Contrave Launch Strategy: Comfortable Drug To Combat Effects Of Comfort Food
Orexigen and marketing partner Takeda’s efforts “will be scaled like a typical diabetes launch,” making it much larger than other recent obesity launches.
You may also be interested in...
Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.
Next PrecisionFDA challenge aims to detect ‘adverse event anomalies’ including manufacturer-specific patterns and drug-drug interactions.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.